PHILIP NEEDLEMAN
Pharmacy in Saint Louis, MO

2005010, May 19, 2005

May 12, 2004

10/844269

Philip Needleman - Creve Coeur MO, US
Mark Obukowicz - Kirkwood MO, US

Pharmacia Corporation - St. Louis MO

A61K031/50, A61K031/425, A61K031/415, A61K031/4439, A61K031/426, A61K031/365, A61K031/18

514247000, 514340000, 514369000, 514406000, 514471000, 514602000, 514374000

The present invention provides compositions and methods for the treatment of ischemic mediated central nervous system disorders. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder comprising the administration to a subject of a peroxisome proliferator activated receptor agonist in combination with a cyclooxygenase-2 selective inhibitor.

6132697, Oct 17, 2000

Jun 5, 1997

8/870042

Ananthachari Srinivasan - St. Charles MO
Larry P. Feigen - Wauconda IL
Daniel Lee Flynn - Clarkson Valley MO
Jeffery Alan Zablocki - LaFayette CO
Philip Needleman - Creve Coeur MO
Michelle A. Schmidt - Belleville IL

G. D. Searle & Co. - Chicago IL

A61K 5100, A61K 3800, C07F 500

424 169

A radiopharmaceutical capable of localizing at a site of thrombus containing activated platelets within a mammalian body is provided wherein the radiopharmaceutical comprises a linear peptidomimetic containing ligand capable of specifically binding to the GPIIb/IIIa integrin receptor of platelets in the thrombus and a radionuclide covalently bound to the peptidomimetic containing ligand. The ligand compositions of the invention are provided complexed with a selected metal radionuclide to form a diagnostic or therapeutic radiopharmaceutical to image a site of thrombus or provide radiotherapy to the site of thrombus, respectively. Methods of imaging a site of thrombus in a mammalian body by administering a diagnostically effective amount of the radiopharmaceutical composition of this invention complexed with a selected diagnostic metal radionuclide and methods of providing therapy to a site of thrombus in a mammalian body by administering a therapeutically effective amount of the radiopharmaceutical composition of this invention complexed with a selected therapeutic metal radionuclide are also provided as well as kits for preparing such radiopharmaceutical compositions.

2003010, May 29, 2003

Aug 31, 1999

09/386591

PHILIP NEEDLEMAN - CREVE COEUR MO, US
KEVIN GLENN - MARYLAND HEIGHTS MO, US

A61K048/00, C07H021/04

514/044000, 536/023530, 536/023200

A process for inducing the production of antibodies that bind to cholesteryl ester transfer protein (CETP) is disclosed. That process comprises the steps of: (a) immunizing a mammal with an inoculum containing a recombinant DNA molecule that comprises a DNA sequence that contains (i) a sequence encoding a CETP immunogen that is linked to (ii) a promoter sequence that controls expression of the CETP immunogen, the recombinant DNA molecule being dissolved or dispersed in a vehicle; and (b) maintaining the immunized mammal for a time period sufficient to induce the production of antibodies that bind to CETP, and preferably lessen the transfer of cholesteryl esters from HDL where the blood of the mammal itself contains CETP. Immunogens, inocula, DNA segments, and recombinant DNA molecule vectors useful for carrying out the invention are also disclosed.

2003002, Feb 6, 2003

Aug 31, 1999

09/387340

PHILIP NEEDLEMAN - CREVE COEUR MO, US
KEVIN GLENN - MARYLAND HEIGHTS MO, US
ELAINE KRUL - WARSON WOODS MO, US
EDWARD P. GAMSON - HIGHLAND PARK IL, US

A61K039/00, A61K039/38

424/184100

A process for increasing the concentration of HDL cholesterol in the blood of a mammal whose blood contains cholesterol ester transfer protein (CETP) is contemplated. That process comprises the steps of: (a) immunizing the mammal with an inoculum containing a CETP immunogen that is an immunogenic polypeptide having a CETP amino acid residue sequence that is covalently bonded to an exogenous antigenic carrier polypeptide and is dissolved or dispersed in a vehicle; and (b) maintaining the immunized mammal for a time period sufficient for said immunogenic polypeptide to induce the production of antibodies that bind to CETP and lessen the transfer of cholesteryl esters from HDL. Immunogens, inocula and DNA segments useful for carrying out the invention are also disclosed.

2007007, Mar 29, 2007

Mar 23, 2006

11/387554

Barbara Roniker - Chicago IL, US
Richard LaChapelle - Wilmette IL, US
Daniel Connolly - Ballwin MO, US
Karen Seibert - St. Louis MO, US
Philip Needleman - Creve Coeur MO, US

A61K 31/50, A61K 31/4439, A61K 31/415, A61K 31/421, A61K 31/42, A61K 31/401, A61K 31/366, A61K 31/365, A61K 31/22

514247000, 514357000, 514406000, 514341000, 514423000, 514460000, 514471000, 514548000, 514374000, 514378000

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders.

2003019, Oct 9, 2003

Jan 21, 2003

10/348300

Philip Needleman - Creve Coeur MO, US
Barry Hafkin - Danbury CT, US

A61K038/14, A61K031/704, A61K031/496, A61K031/416, A61K031/4709, A61K031/545, A61K031/43

514/008000, 514/037000, 514/192000, 514/200000, 514/253080, 514/312000, 514/300000, 514/406000

The present invention provides compositions and methods for treating or preventing bacterial infections. The compositions and methods include the use of antibiotics and cyclooxygenase inhibitors.

2002003, Mar 21, 2002

Sep 6, 2001

09/946623

Barbara Roniker - Chicago IL, US
Richard LaChapelle - Wilmette IL, US
Daniel Connolly - Ballwin MO, US
Karen Seibert - St. Louis MO, US
Philip Needleman - Creve Coeur MO, US

A61K031/18

514/605000

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders.

4557864, Dec 10, 1985

Jul 26, 1984

6/634858

Philip Needleman - Olivette MO

Washington University - St. Louis MO

C07C10352

2601125R

Novel atrial peptides having useful natriuretic activity are disclosed with the following amino acid sequence: R. sub. 1 -cys-phe-gly-gly-arg-ile-asp-arg-ile-gly-ala-gln-ser-gly-leu-gly-cys-asn-R. sub. 2 wherein R. sub. 1 =H, ser, ser-ser, and R. sub. 2 =OH, ser, ser-phe-arg, ser-phe-arg-tyr, or the physiologically acceptable salts, esters or amides thereof.

4508712, Apr 2, 1985

May 4, 1984

6/607064

Philip Needleman - Olivette MO

Washington University - St. Louis MO

A61K 3700, C07C10352

514 11

A novel atrial peptide having useful natriuretic, diuretic and vasodilating activity is disclosed with the following amino acid sequence: ##STR1##.

4496544, Jan 29, 1985

Jan 10, 1984

6/569684

Philip Needleman - Olivette MO

Washington University - St. Louis MO

A61K 3700, C07C10352

514 13

Novel atrial peptides having useful natriuretic activity are disclosed with the following amino acid sequence: R. sub. 1 -cys-phe-gly-gly-arg-ile-asp-arg-ile-gly-ala-gln-ser-gly-leu-gly-cys-asn-R. sub. 2 wherein R. sub. 1 =H, ser, ser-ser, and R. sub. 2 =OH, ser, ser-phe-arg, ser-phe-arg-tyr, or the physiologically acceptable salts, esters or amides thereof.